At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Ibritumomab Tiuxetan (Zevalin) +1 moredrug
Likely dose
Ibritumomab Tiuxetan (Zevalin) 1.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Zevalin for the Treatment of Early-Stage Indolent Lymphomas
In Brief
A Phase 2 clinical trial evaluating Ibritumomab Tiuxetan (Zevalin) and Rituximab for Lymphoma. Completed, enrolled 31 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to find out if giving (Rituxan) rituximab with 90Y (ibritumomab tiuxetan) (90 Y Zevalin®) may be effective in treating low-grade lymphoma. The safety of this combination treatment will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsBiogen, CTI BioPharma
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJun 2007
Primary CompletionApr 2015
Study CompletionAug 2022
TodayJul 2026
First PostedJun 28, 2007
Enrollment StartJun 1, 2006
Primary CompletionApr 1, 2015
Study CompletionAug 11, 2022
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 19.0 years ago
Interventions
Ibritumomab Tiuxetan (Zevalin)drug
111In Zevalin (5 mCi of \^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1. 90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8.
Rituximabdrug
250 mg/m\^2 Intravenously Over 4-6 Hours On Days 1 and 8.